摘要
目的探究阿奇霉素序贯治疗小儿肺炎支原体肺炎的临床疗效。方法60例小儿肺炎支原体肺炎患儿,按照随机原则分为对照组与观察组,各30例。对照组采用常规药物治疗,观察组采用阿奇霉素序贯治疗。对比两组临床疗效、治疗前后炎症因子水平[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(CRP)]、症状消失时间、不良反应。结果观察组治疗总有效率93.33%高于对照组的73.33%,差异有统计学意义(P<0.05)。治疗后,两组TNF-α、IL-6、CRP水平均低于本组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。观察组肺部啰音、咳嗽及发热症状消失时间分别为(4.21±0.31)、(5.20±1.22)、(3.62±0.23)d,均短于对照组的(5.77±0.33)、(7.14±2.40)、(4.93±0.32)d,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论临床面对小儿肺炎支原体肺炎患儿时,采用阿奇霉素序贯治疗,能减轻炎症反应,促进症状消退,安全性较高,疗效确切,值得推广。
Objective To investigate the clinical efficacy of azithromycin sequential therapy in children with Mycoplasma pneumoniae pneumonia.Methods A total of 60 children with mycoplasma pneumoniae pneumonia were randomly divided into the control group and the observation group,with 30 cases in each group.The control group was treated with conventional drugs,and the observation group was treated with azithromycin sequential therapy.The clinical efficacy,inflammatory factor levels[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),C-reactive protein(CRP)]before and after treatment,symptom disappearance time,and occurrence of adverse reactions were compared between the two groups.Results The total effective rate 93.33%of the observation group was higher than 73.33%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of TNF-α,IL-6 and CRP in the two groups were lower than those before treatment in this group,and the observation group was lower than the control group.The differences were statistically significant(P<0.05).The disappearance time of pulmonary rales,cough and fever symptoms in the observation group were(4.21±0.31),(5.20±1.22),and(3.62±0.23)d,which were shorter than(5.77±0.33),(7.14±2.40),and(4.93±0.32)d in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Azithromycin sequential therapy has definite efficacy on children with Mycoplasma pneumoniae pneumonia,and can reduce the inflammatory response and promote the subsidence of symptoms with high safety,which is worthy of promotion.
作者
梁晓燕
LIANG Xiao-yan(Department of Pediatrics,Suzhou Hospital Affiliated to Nanjing Medical University,Suzhou 215002,China)
出处
《中国现代药物应用》
2022年第18期121-124,共4页
Chinese Journal of Modern Drug Application
关键词
小儿肺炎
支原体肺炎
阿奇霉素
序贯治疗
治疗效果
不良反应
Pediatric pneumonia
Mycoplasma pneumonia
Azithromycin
Sequential therapy
Therapeutic effect
Adverse reactions
